NCT02199652

Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)

Reducing Suicidal Ideation Through Treatment of Nightmares-PTSD

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Augusta University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Patients with PTSD, and frequent nightmares, and mild-moderate suicidal ideation, who are already taking a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) will be randomized to either prazosin or placebo. The investigators hypothesize that patients receiving prazosin will have a greater reduction in suicidal ideation.

Conditions

• Post Traumatic Stress Disorder
• Suicidal Ideation
• Nightmares

Interventions

Type	Name	Description
DRUG	Prazosin
DRUG	Placebo

Timeline

• Start date: 2014-03-01
• Primary completion: 2017-09-01
• Completion: 2017-12-01
• First posted: 2014-07-24
• Last updated: 2018-09-18
• Results posted: 2018-08-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study